<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="study:id" content="pet-adapted-low-risk-dlbcl-shi">
    <meta name="study:title" content="PF916 - Positron emission tomography-adapted therapy in low-risk diffuse large B-cell lymphoma: 4-year results of a randomized, phase III, non-inferiority trial">
    <meta name="study:fileName" content="Abstracts/PET-ADAPTED-LOW-RISK-DLBCL-SHI.html">
    <meta name="study:cancerTypes" content="DLBCL,LBCL,B-NHL">
    <meta name="study:lineOfTherapy" content="1L">
    <meta name="study:evidenceType" content="Clinical trial"> <meta name="study:drugs" content="Rituximab,Monoclonal Antibody,Cyclophosphamide,Doxorubicin,Vincristine,Prednisone,Chemotherapy,CIT,R-CHOP">

    <title>PF916: PET-Adapted Therapy in Low-Risk DLBCL (Shi) - SOBI Themed</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://d3js.org/d3.v7.min.js"></script>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="abstract_styles.css">
</head>
<body class="abstract-page-body">
    <div class="slide-container">
        <div class="visual-abstract-container">
            <h2 class="visual-abstract-title">Visual Summary: PF916 - PET-Adapted Therapy in Low-Risk DLBCL (4-Year Results)</h2>
            <div class="visual-abstract-grid">
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path d="M12 6.096c-1.058 0-2.02.468-2.704 1.248-.685.78-.996 1.788-.996 2.856s.311 2.076.996 2.856C9.98 13.84 10.942 14.31 12 14.31s2.02-.468 2.704-1.248.996-1.788.996-2.856-.311-2.076-.996-2.856C14.02 6.564 13.058 6.096 12 6.096zM12 12.81c-.53 0-1.008-.222-1.352-.588-.344-.366-.528-.852-.528-1.422s.184-1.056.528-1.422C10.992 9.012 11.47 8.79 12 8.79s1.008.222 1.352.588.528.852.528 1.422-.184-1.056-.528 1.422C13.008 12.588 12.53 12.81 12 12.81zm6.708 3.672A7.47 7.47 0 0012.024 15c-1.404 0-2.706.39-3.816 1.056A4.476 4.476 0 004.5 19.686V21h15v-1.314a4.476 4.476 0 00-3.792-3.624zM6.024 16.56c.84-.468 1.848-.768 2.904-.924A5.928 5.928 0 0112.024 15a5.928 5.928 0 013.096.636c1.056.156 2.064.456 2.904.924A2.988 2.988 0 0019.5 18.018V19.5h-15v-1.482a2.988 2.988 0 001.524-2.458zM4.5 7.032c0-1.068.312-2.076.996-2.856S7.2 3 8.256 3A7.47 7.47 0 0112.024 1.5c1.404 0 2.706.39 3.816 1.056A4.476 4.476 0 0119.5 6.186V7.5H4.5v-.468zM18 4.56c-.84.468-1.848.768-2.904-.924A5.928 5.928 0 0012.024 6a5.928 5.928 0 00-3.096.636 7.524 7.524 0 00-2.904.924A2.988 2.988 0 014.5 7.482V6H3V4.5A1.5 1.5 0 014.5 3h15A1.5 1.5 0 0121 4.5V6h-1.5v1.482a2.988 2.988 0 01-1.524 2.458L18 4.56z" />
                    </svg>
                    <h4>Population & Aim (N=287 ITT)</h4>
                    <p>Low-risk (IPI 0-1), non-bulky DLBCL with interim PET-CR. Aim: Compare 4 vs 6 R-CHOP cycles (long-term f/u).</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path fill-rule="evenodd" d="M4.5 3.75A.75.75 0 003.75 3H2.25a.75.75 0 000 1.5H4.5V12H2.25a.75.75 0 000 1.5H4.5V21h1.5V3.75A.75.75 0 004.5 3.75zM8.25 3a.75.75 0 00-.75.75v16.5a.75.75 0 001.5 0V3.75A.75.75 0 008.25 3zM12 3.75A.75.75 0 0011.25 3h-1.5a.75.75 0 000 1.5H12V12h-1.5a.75.75 0 000 1.5H12V21h1.5V3.75A.75.75 0 0012 3.75zm3.75-0.75A.75.75 0 0015 3.75v16.5a.75.75 0 001.5 0V3.75a.75.75 0 00-.75-.75zm3.75.75A.75.75 0 0018.75 3H18v18h1.5V3.75A.75.75 0 0018.75 3z" clip-rule="evenodd" />
                    </svg>
                    <h4>Intervention (Randomized 1:1)</h4>
                    <p>Arm 1: 4xR-CHOP + 4xR<br>Arm 2: 6xR-CHOP + 2xR<br>(Post 4xR-CHOP interim PET-CR)</p>
                </div>
                <div class="visual-abstract-item">
                     <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path d="M3 13.5a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 13.5zM3 8.25a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 8.25zM3 18.75a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 18.75zM20.25 3a.75.75 0 00-.75.75v16.5a.75.75 0 001.5 0V3.75a.75.75 0 00-.75-.75z" />
                        <path fill-rule="evenodd" d="M9.97 4.28a.75.75 0 01.75-.75H12a.75.75 0 01.75.75v10.174l3.108-3.293a.75.75 0 111.084 1.038l-4.5 4.75a.75.75 0 01-1.084 0l-4.5-4.75a.75.75 0 111.084-1.038L9.97 14.454V4.28z" clip-rule="evenodd" />
                    </svg>
                    <h4>Key Efficacy (Median F/U: 71.5 mo)</h4>
                    <p>4-yr PFS: <span class="highlight-value">92%</span> (both arms)<br>4-yr OS: <span class="highlight-value">98%</span> (both arms)<br>No significant differences.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M12 2.25c-5.385 0-9.75 4.365-9.75 9.75s4.365 9.75 9.75 9.75 9.75-4.365 9.75-9.75S17.385 2.25 12 2.25zm-.092 14.444a.75.75 0 01-.092 0l-3.75-3.75a.75.75 0 111.06-1.06L12 14.813l3.182-3.182a.75.75 0 111.06 1.06l-3.75 3.75a.75.75 0 01-.53.22z" clip-rule="evenodd" />
                    </svg>
                    <h4>Conclusion</h4>
                    <p>4xR-CHOP + 4xR provides comparable long-term efficacy to 6xR-CHOP + 2xR in low-risk, non-bulky DLBCL with interim PET-CR.</p>
                </div>
            </div>
        </div>

        <div class="text-center mb-8">
            <h1 class="abstract-header-title">PF916 - Positron emission tomography-adapted therapy in low-risk diffuse large B-cell lymphoma: 4-year results of a randomized, phase III, non-inferiority trial</h1>
            <p class="abstract-sub-header">Qing Shi, Di Fu, Pengpeng Xu, et al.</p>
            <p class="abstract-meta-info mt-2">EHA 2025 Congress | Abstract #PF916 | Poster Presentation</p>
        </div>

        <div class="grid md:grid-cols-2 gap-x-8 gap-y-6">
            <div>
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Background</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Goal: Maintain efficacy while minimizing chemotherapy in IPI low-risk, non-bulky DLBCL.</li>
                        <li>Previous results of this trial: Reducing 6 R-CHOP cycles to 4 achieved comparable efficacy with fewer AEs in patients with interim PET-CT confirmed CR.</li>
                        <li>Long-term follow-up is needed to validate these findings.</li>
                    </ul>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Aims</h2>
                    <p class="text-sm mb-1">To compare four cycles of chemotherapy to six cycles in non-bulky, low-risk (IPI = 0-1) DLBCL patients with negative interim PET-CT, through extended follow-up.</p>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Methods & Study Design</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 mb-3 pl-2">
                        <li>Open-label, randomized, phase III, non-inferiority trial (NCT02752815).</li>
                        <li>Patients: Aged 14-75 yrs, newly diagnosed low-risk DLBCL (IPI 0-1), non-bulky.</li>
                        <li>Initial Treatment: All patients received 4 cycles of R-CHOP.</li>
                        <li>Randomization (1:1) for PET-CT CR patients after 4 R-CHOP cycles:
                            <ul class="list-circle list-inside ml-4">
                                <li>Arm 1 (4R-CHOP+4R): 4 cycles of Rituximab.</li>
                                <li>Arm 2 (6R-CHOP+2R): 2 additional cycles of R-CHOP + 2 cycles of Rituximab.</li>
                            </ul>
                        </li>
                        <li>Primary Endpoint: Progression-Free Survival (PFS).</li>
                        <li>Analysis: Intention-to-treat (ITT). Data cutoff: Oct 30, 2024.</li>
                    </ul>
                     <div class="study-design-schema">
                        <h3 class="schema-title">PET-Adapted Therapy Trial Design</h3>
                        <div class="schema-enrollment">
                            <strong>Eligible Patients (N=287 ITT)</strong>
                            <span>Newly Diagnosed Low-Risk (IPI 0-1), Non-Bulky DLBCL</span>
                            <span>Aged 14-75 years</span>
                        </div>
                        <div class="schema-arrow-down">‚ñº</div>
                        <div class="schema-phase-group">
                            <div class="schema-phase" style="flex-basis: 100%;">
                                <strong>Induction (All Patients)</strong>
                                <span>4 cycles of R-CHOP</span>
                            </div>
                        </div>
                        <div class="schema-arrow-down">‚ñº</div>
                        <div class="schema-assessment" style="background-color: var(--sobi-light-orange-bg); border-color: var(--sobi-orange);">
                            <strong>Interim PET-CT Assessment</strong>
                            <span>(After 4 cycles R-CHOP)</span>
                        </div>
                        <div class="schema-arrow-down">‚ñº</div>
                         <p class="text-center text-sm my-1">Patients achieving PET-CT confirmed CR randomized 1:1</p>
                        <div class="schema-phase-group">
                            <div class="schema-phase" style="flex-basis: 48%; background-color: var(--sobi-light-teal-bg);">
                                <strong>Arm 1: 4R-CHOP + 4R</strong>
                                <span>(Total: 4 R-CHOP + 4 Rituximab)</span>
                            </div>
                             <div style="writing-mode: vertical-rl; text-orientation: mixed; margin: auto 5px; font-weight:bold;">OR</div>
                            <div class="schema-phase" style="flex-basis: 48%; background-color: var(--sobi-light-orange-bg);">
                                <strong>Arm 2: 6R-CHOP + 2R</strong>
                                 <span>(Total: 6 R-CHOP + 2 Rituximab)</span>
                            </div>
                        </div>
                        <div class="schema-assessment-points">
                           <span>Primary Endpoint: PFS</span>
                           <span>Secondary: OS, Relapse Rates</span>
                        </div>
                    </div>
                </div>
            </div>

            <div>
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Efficacy Results (Median F/U: 71.5 months)</h2>
                    <div class="grid grid-cols-1 sm:grid-cols-2 gap-4 mb-4">
                        <div class="infographic-item orange-theme">
                            <div class="infographic-icon icon-orange">üìà</div>
                            <div class="infographic-value">92%</div>
                            <div class="infographic-label">4-Year PFS (Both Arms)</div>
                        </div>
                        <div class="infographic-item teal-theme">
                            <div class="infographic-icon icon-teal">‚ù§Ô∏è</div>
                            <div class="infographic-value">98%</div>
                            <div class="infographic-label">4-Year OS (Both Arms)</div>
                        </div>
                    </div>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2 mb-3">
                        <li>4-year PFS:
                            <ul class="list-circle list-inside ml-4">
                                <li>4R-CHOP+4R arm: 92% (95% CI, 88%-97%)</li>
                                <li>6R-CHOP+2R arm: 92% (95% CI, 87%-96%)</li>
                            </ul>
                        </li>
                        <li>4-year OS:
                             <ul class="list-circle list-inside ml-4">
                                <li>4R-CHOP+4R arm: 98% (95% CI, 96%-100%)</li>
                                <li>6R-CHOP+2R arm: 98% (95% CI, 96%-100%)</li>
                            </ul>
                        </li>
                        <li>No significant differences in PFS or OS between arms.</li>
                        <li>Relapse rates after CR were similar in both arms.</li>
                    </ul>
                     <div class="grid grid-cols-1 md:grid-cols-2 gap-4 mt-4">
                        <div class="km-plot-container zoomable-image-container">
                            <img src="https://storage.googleapis.com/generativeai-downloads/ESH2025/PF916_PFS_KM.png" alt="Progression-Free Survival Kaplan-Meier Curve" class="zoomable-image" onerror="this.onerror=null; this.src='https://placehold.co/400x300/E0F2F7/0A2F5C?text=PFS+Curve+Not+Available';">
                            <p class="text-xs text-center mt-1">Progression-Free Survival (Adapted from Abstract Figure 1)</p>
                        </div>
                        <div class="km-plot-container zoomable-image-container">
                             <img src="https://storage.googleapis.com/generativeai-downloads/ESH2025/PF916_OS_KM.png" alt="Overall Survival Kaplan-Meier Curve" class="zoomable-image" onerror="this.onerror=null; this.src='https://placehold.co/400x300/FFF0E5/0A2F5C?text=OS+Curve+Not+Available';">
                            <p class="text-xs text-center mt-1">Overall Survival (Adapted from Abstract Figure 1)</p>
                        </div>
                    </div>
                </div>
                 <div class="abstract-card">
                    <h2 class="abstract-section-title">Safety Summary</h2>
                     <p class="text-sm">A total of 12 (4%) patients died:</p>
                     <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>7 due to disease progression.</li>
                        <li>3 due to pulmonary infection (1 during treatment, 2 during COVID-19 pandemic).</li>
                        <li>(Detailed AE comparison between arms not provided in this extended follow-up abstract, but previous report indicated fewer AEs with 4 cycles).</li>
                    </ul>
                </div>
            </div>
        </div>

        <div class="abstract-card mt-6">
            <h2 class="abstract-section-title">Summary & Conclusion</h2>
            <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                <li>Four cycles of R-CHOP plus four cycles of rituximab provide long-term clinical efficacy comparable to six cycles of R-CHOP plus two cycles of rituximab in low-risk, non-bulky DLBCL patients with negative interim PET-CT.</li>
                <li>This interim PET-adapted strategy ensures durable remission and offers new insights into the management of low-risk DLBCL.</li>
            </ul>
        </div>

        <div class="abstract-card mt-6 abbreviations-list">
            <p>AE, Adverse Event; CHOP, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone; CI, Confidence Interval; CIT, Chemoimmunotherapy; CR, Complete Remission; DLBCL, Diffuse Large B-Cell Lymphoma; F/U, Follow-up; IPI, International Prognostic Index; ITT, Intention-To-Treat; OS, Overall Survival; PET-CT, Positron Emission Tomography-Computed Tomography; PFS, Progression-Free Survival; R, Rituximab; R-CHOP, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone.</p>
        </div>

        <div class="abstract-card mt-6 reference-section">
            <h2 class="abstract-section-title">
                Reference
                <button id="copyReferenceBtn" class="copy-reference-button" title="Copy Reference">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor">
                        <path d="M7 3.5A1.5 1.5 0 018.5 2h3.879a1.5 1.5 0 011.06.44l3.122 3.121A1.5 1.5 0 0117 6.621V16.5a1.5 1.5 0 01-1.5 1.5h-7A1.5 1.5 0 017 16.5v-13z" />
                        <path d="M4.5 6A1.5 1.5 0 003 7.5v10A1.5 1.5 0 004.5 19h7a1.5 1.5 0 001.5-1.5v-2.5a.75.75 0 00-1.5 0v2.5a.5.5 0 01-.5.5h-7a.5.5 0 01-.5-.5v-10a.5.5 0 01.5-.5h2.5a.75.75 0 000-1.5H4.5z" />
                    </svg>
                    Copy
                </button>
            </h2>
            <p id="referenceSectionContent">
                Shi Q, Fu D, Xu P, et al. Positron emission tomography-adapted therapy in low-risk diffuse large B-cell lymphoma: 4-year results of a randomized, phase III, non-inferiority trial. Abstract #PF916 presented at European Haematology Association (EHA) June 12‚Äì15, 2025, Milan, Italy.
            </p>
        </div>

        <div class="abstract-footer-info">
            <p>EHA 2025 Congress | Abstract #PF916 | Abstract Release: 05/14/2025 | Presentation: 06/13/2025</p>
            <p>NCT02752815 | For Research & Informational Purposes Only.</p>
        </div>
    </div>

    <script defer src="abstract_features.js"></script>
    </body>
</html>
